Header Logo

Connection

PAOLO ANDERLINI to Graft vs Host Disease

Back to Details
This is a "connection" page, showing publications PAOLO ANDERLINI has written about Graft vs Host Disease.
PAOLO ANDERLINI
Connection Strength
1.817
Graft vs Host Disease
  1. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant. 2004 Sep; 34(6):511-4.
    View in: PubMed
    Score: 0.109
  2. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther. 2022 08; 28(8):501.e1-501.e7.
    View in: PubMed
    Score: 0.093
  3. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2022 07; 28(7):395.e1-395.e11.
    View in: PubMed
    Score: 0.093
  4. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. 2021 06; 56(6):1316-1324.
    View in: PubMed
    Score: 0.085
  5. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther. 2021 03; 27(3):272.e1-272.e5.
    View in: PubMed
    Score: 0.084
  6. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020 08; 26(8):1439-1445.
    View in: PubMed
    Score: 0.081
  7. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
    View in: PubMed
    Score: 0.075
  8. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
    View in: PubMed
    Score: 0.074
  9. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biol Blood Marrow Transplant. 2019 02; 25(2):270-278.
    View in: PubMed
    Score: 0.072
  10. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015 Sep; 2(9):e367-75.
    View in: PubMed
    Score: 0.058
  11. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014 Oct 02; 124(14):2306-12.
    View in: PubMed
    Score: 0.054
  12. Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica. 2014 Dec; 99(12):1868-75.
    View in: PubMed
    Score: 0.054
  13. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302.
    View in: PubMed
    Score: 0.042
  14. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009 Sep 24; 114(13):2606-16.
    View in: PubMed
    Score: 0.038
  15. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Apr 30; 113(18):4144-52.
    View in: PubMed
    Score: 0.037
  16. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant. 2007 Apr; 13(4):469-77.
    View in: PubMed
    Score: 0.032
  17. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand? Biol Blood Marrow Transplant. 2006 Jun; 12(6):599-602.
    View in: PubMed
    Score: 0.031
  18. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):37-40.
    View in: PubMed
    Score: 0.030
  19. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006 Apr 15; 107(8):3074-80.
    View in: PubMed
    Score: 0.030
  20. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005 May; 35(10):943-51.
    View in: PubMed
    Score: 0.029
  21. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Aug 01; 104(3):649-54.
    View in: PubMed
    Score: 0.026
  22. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004 Mar; 10(3):178-85.
    View in: PubMed
    Score: 0.026
  23. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003 Mar; 31(6):459-65.
    View in: PubMed
    Score: 0.025
  24. Scleritis as the initial clinical manifestation of graft-versus-host disease after allogenic bone marrow transplantation. Am J Ophthalmol. 2002 Jun; 133(6):843-5.
    View in: PubMed
    Score: 0.023
  25. Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status. Cytotherapy. 2002; 4(3):241-51.
    View in: PubMed
    Score: 0.023
  26. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15; 98(13):3595-9.
    View in: PubMed
    Score: 0.023
  27. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001 Nov 15; 98(10):2900-8.
    View in: PubMed
    Score: 0.022
  28. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Sep 15; 98(6):1695-700.
    View in: PubMed
    Score: 0.022
  29. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000 Oct; 111(1):18-29.
    View in: PubMed
    Score: 0.021
  30. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20.
    View in: PubMed
    Score: 0.021
  31. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7.
    View in: PubMed
    Score: 0.020
  32. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8.
    View in: PubMed
    Score: 0.019
  33. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70.
    View in: PubMed
    Score: 0.019
  34. Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2019 03; 25(3):488-495.
    View in: PubMed
    Score: 0.018
  35. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
    View in: PubMed
    Score: 0.017
  36. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017 07; 102(7):1291-1298.
    View in: PubMed
    Score: 0.016
  37. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.
    View in: PubMed
    Score: 0.016
  38. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15.
    View in: PubMed
    Score: 0.015
  39. Outcomes of Haploidentical Stem Cell Transplantation for?Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. 2016 Mar; 22(3):493-8.
    View in: PubMed
    Score: 0.015
  40. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8.
    View in: PubMed
    Score: 0.015
  41. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1790-5.
    View in: PubMed
    Score: 0.014
  42. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
    View in: PubMed
    Score: 0.014
  43. Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biol Blood Marrow Transplant. 2013 Mar; 19(3):474-80.
    View in: PubMed
    Score: 0.012
  44. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012 Oct 18; 367(16):1487-96.
    View in: PubMed
    Score: 0.012
  45. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6.
    View in: PubMed
    Score: 0.011
  46. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. 2012 Feb; 47(2):212-6.
    View in: PubMed
    Score: 0.011
  47. Unrelated donor transplantation for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1067-71.
    View in: PubMed
    Score: 0.010
  48. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1122-9.
    View in: PubMed
    Score: 0.010
  49. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009 Jan; 15(1):109-17.
    View in: PubMed
    Score: 0.009
  50. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6.
    View in: PubMed
    Score: 0.009
  51. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007 Nov 01; 110(9):3456-62.
    View in: PubMed
    Score: 0.008
  52. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2007 Sep; 40(5):431-5.
    View in: PubMed
    Score: 0.008
  53. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 Jul; 40(2):125-36.
    View in: PubMed
    Score: 0.008
  54. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep; 38(6):421-6.
    View in: PubMed
    Score: 0.008
  55. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
    View in: PubMed
    Score: 0.007
  56. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004 Jan; 32(1):28-35.
    View in: PubMed
    Score: 0.007
  57. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003 Nov 15; 102(10):3829-36.
    View in: PubMed
    Score: 0.006
  58. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002 Sep; 30(6):367-73.
    View in: PubMed
    Score: 0.006
  59. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002; 8(9):477-85.
    View in: PubMed
    Score: 0.006
  60. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7.
    View in: PubMed
    Score: 0.005
  61. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher. 2001; 16(2):82-7.
    View in: PubMed
    Score: 0.005
  62. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999 Nov; 10(11):1293-9.
    View in: PubMed
    Score: 0.005
  63. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
    View in: PubMed
    Score: 0.005
  64. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug; 16(8):2817-24.
    View in: PubMed
    Score: 0.004
  65. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6.
    View in: PubMed
    Score: 0.004
  66. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.
    View in: PubMed
    Score: 0.004
  67. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.